Tumor Necrosis Factor-α Gene Polymorphisms and Risk of Oral Cancer: Evidence from a Meta-analysis

Chen, Fangchun; Zhang, Fan; Zhang, Zhi-jiao; Meng, Siying; Wang, Yan; Xiang, Xue-Rong; Wang, Chun; Tang, Yanhui

doi:10.7314/apjcp.2013.14.12.7243

Cited by 19 publications

(8 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The TRAIL may be used as an antitumor factor on the tumor cells and their metastases, oral cancer, glioma, and cervical carcinoma, because it causes death only in the tumor cells, not in the normal cells . Our present findings suggest that our glycodendrimers increase TRAIL expression.…”

Section: Resultssupporting

confidence: 52%

PPI‐G4 Glycodendrimers Upregulate TRAIL‐Induced Apoptosis in Chronic Lymphocytic Leukemia Cells

Franiak-Pietryga

Ostrowska

Maciejewski

et al. 2016

Macromolecular Bioscience

View full text Add to dashboard Cite

Although chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western world, it remains incurable with conventional chemotherapeutic agents. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is an antitumor candidate in cancer therapy. This study examines the proapoptotic effects of poly(propylene imine) (PPI) glycodendrimers modified with the maltotriose residues (PPI-G4-OS-Mal-III and PPI-G4-DS-Mal-III) on the TNF family in CLL cells. The combination of an understanding of the signaling pathways associated with CLL and the development of a molecular profiling is a key issue for the design of personalized approaches to therapy. Gene expression is determined with two-color microarray 8 × 60K. The findings indicate that PPI-G4-OS/DS-Mal-III affect gene expression from the TRAIL apoptotic pathway and exert a strong effect on CLL cells comparable with fludarabine. Dendrimer-targeted technology may well prove to bridge the gap between the ineffective treatment of today and the effective personalized therapy of the future.

show abstract

Section: Resultssupporting

confidence: 52%

PPI‐G4 Glycodendrimers Upregulate TRAIL‐Induced Apoptosis in Chronic Lymphocytic Leukemia Cells

Franiak-Pietryga

Ostrowska

Maciejewski

et al. 2016

Macromolecular Bioscience

View full text Add to dashboard Cite

show abstract

“…A significant difference between LSCC/OSCC risks and the rs1800629 polymorphism was found under the AA vs GG, and AA vs GG+GA models; this corresponds with previous data on the link of rs1800629 and the risk of upper aero-digestive tract or head/neck SCC [ 25 , 26 ]. However, in 2013, Chen et al performed a meta-analysis to analyze the association between rs1800629 and oral cancer, and observed a negative association between rs1800629 and OSCC [ 27 ]. Different selection criteria may contribute to this discrepancy.…”

Section: Discussionmentioning

confidence: 99%

Genetic association between TNF-α promoter polymorphism and susceptibility to squamous cell carcinoma, basal cell carcinoma, and melanoma: A meta-analysis

Liu

Liu³

2017

Oncotarget

View full text Add to dashboard Cite

Tumor necrosis factor-alpha (TNF-α) is a multifunctional pro-inflammatory cytokine that plays an important role in cancer development. We performed a meta-analysis to assess the relationship between single nucleotide polymorphisms in the TNF-α promoter region (rs1800629 and rs361525) and susceptibility to squamous cell carcinoma (SCC), basal cell carcinoma (BCC) and melanoma. After database retrieval, article selection, data extraction, and quality assessment, 20 articles comprising 4865 cases and 6329 controls were included in this study. rs1800629 was associated with an increased overall risk of SCC, lung SCC, and oral SCC in the AA vs G and AA vs GG+GA genetic models (all OR>1, Passociation<0.05). No increased risk of skin SCC, skin BCC or melanoma was observed (all Passociation>0.05). Rs361525 was not associated with overall SCC risk in the allele, heterozygote, dominant, recessive, or carrier model (all Passociation>0.05). Begg's and Egger's tests (PBegg>0.05; PEgger>0.05) demonstrated there was no significant publication bias. These data indicate that the AA genotype of TNF-α rs1800629, but not rs361525, is associated with an increased risk of SCC, suggesting it could potentially serve as a prognostic marker for predicting SCC risk.

show abstract

“…Kaluza et al (2000) reported that the G allele of TNF-α (-238) polymorphism caused a significant increase in the transcription of the TNF-α gene [47]. The frequency of the rare TNF-α (-238) A allele was significantly lower in OSCC patients compared with controls [10,18]. The functional consequences of the TNF-α (-238) A allele are unclear, despite of its known association with a variety of diseases [15,33].…”

Section: Discussionmentioning

confidence: 99%

Association of TNF-α (-238 and -308) promoter polymorphisms with susceptibility of oral squamous cell carcinoma in North Indian population

Singh

Bogra

Chandra

et al. 2015

CBM

View full text Add to dashboard Cite

show abstract

Tumor Necrosis Factor-α Gene Polymorphisms and Risk of Oral Cancer: Evidence from a Meta-analysis

Cited by 19 publications

References 46 publications

PPI‐G4 Glycodendrimers Upregulate TRAIL‐Induced Apoptosis in Chronic Lymphocytic Leukemia Cells

PPI‐G4 Glycodendrimers Upregulate TRAIL‐Induced Apoptosis in Chronic Lymphocytic Leukemia Cells

Genetic association between TNF-α promoter polymorphism and susceptibility to squamous cell carcinoma, basal cell carcinoma, and melanoma: A meta-analysis

Association of TNF-α (-238 and -308) promoter polymorphisms with susceptibility of oral squamous cell carcinoma in North Indian population

Contact Info

Product

Resources

About